PARP1 and ovarian carcinoma: In addition to standard surgical debulking and adjuvant chemotherapy, targeted therapies such as poly ADP–ribose polymerase (PARP) inhibitors (PARPi) and anti-VEGF/VEGF inhibitors have significantly reformed the treatment paradigm of ovarian cancer and markedly prolonged patient progression-free survival (PFS) [2,3].